A comprehensive database developed by King’s College London researchers that features the chemical components found in traditional Chinese medicines has been released to market this month, enabling researchers to explore age-old remedies in the search for tomorrow’s new drugs.
21 October, 2011
DiaGenic reports preliminary positive findings from the collaborative R&D project with Pfizer Inc. where the objective is to identify blood-based biomarkers that may be useful in diagnosing and monitoring Alzheimer’s disease.
19 October, 2011
Diabetes is the theme of this month’s edition of Drug Discovery Today’s Editor’s Choice newsletter. According to the latest data published by the World Health Organization (WHO) approximately 346 million people worldwide are living with diabetes today. If left untreated, chronic hyperglycemia can lead to several macrovascular and microvascular diabetic complications. In spite of the epidemic proportions, exploding healthcare costs, and the great impact this disease has on patients, health care providers, health care systems and insurers, to date, no cures have been identified yet.
18 October, 2011
Roche announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer’s disease.
12 October, 2011
Six new genetic variants will help identify diagnostic markers and drug targets for the 55 million Asian’s affected.
11 October, 2011
New research released today to mark European Week Against Pain reveals that, in more than half of cases, peoples’ levels of pain across Europe are not being adequately assessed.
10 October, 2011
Sanford-Burnham scientists reveal that a hormone called orexin prevents obesity in mice by activating brown fat, a tissue that’s good at burning calories.
06 October, 2011
A study published in Nature online today (Dawson et al. Advanced online Publication, DOI: 10.1038/nature10509) by Cellzome and others has identified that a small molecule inhibitor of BET proteins could potentially be used to treat the aggressive and often incurable mixed lineage (MLL-fusion) leukaemia.
03 October, 2011
Cancer Research Technology (CRT), Cancer Research UK’s commercial arm, has established a group of scientists with expertise in lipid metabolism – getting energy from fats and making building blocks for cell growth – to develop targets for potential new cancer drugs.
03 October, 2011